Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Nephron Clin Pract ; 97(2): c41-8, 2004.
Article in English | MEDLINE | ID: mdl-15218329

ABSTRACT

BACKGROUND/AIM: A defect in skeletal muscle mitochondrial metabolism develops in patients with chronic renal failure on haemodialysis. Treatment with carnitine, a compound essential for normal mitochondrial function, has been suggested to have significant benefits in such patients, so we carried out a study to see if carnitine acts by improving muscle bioenergetics and function. METHODS: In a phase II randomised double-blind trial, patients with end-stage renal disease received placebo or intravenous L-carnitine (20 mg/kg dry body weight three times weekly after haemodialysis) for 16 weeks (n = 13 in each group). 31P magnetic resonance spectroscopy, 1H magnetic resonance imaging and near-infrared spectroscopy were used to measure muscle bioenergetics and function at baseline and at 16 weeks. RESULTS: There were no significant differences between groups at baseline. Mean plasma carnitine rose 10-fold in the carnitine group but was unchanged in the placebo group. L-carnitine had no statistically significant effect on any of the parameters measured. The rate of proton efflux from muscle, as a measure of tissue perfusion, was low in both groups and was not affected by treatment. CONCLUSIONS: The study failed to show any significant effect of 16 weeks' L-carnitine supplementation on these objective measures of muscle metabolism and function. Slow proton efflux from muscle provides evidence supporting low blood flow and, therefore, decreased oxygen availability, as an underlying mechanism for muscle mitochondrial dysfunction in this disorder.


Subject(s)
Carnitine/therapeutic use , Kidney Failure, Chronic/complications , Mitochondria, Muscle/drug effects , Muscle Weakness/drug therapy , Muscle, Skeletal/metabolism , Blood Chemical Analysis , Carnitine/blood , Carnitine/pharmacology , Double-Blind Method , Energy Metabolism/drug effects , Exercise Test , Exercise Tolerance/drug effects , Female , Humans , Kidney Failure, Chronic/metabolism , Kidney Failure, Chronic/therapy , Magnetic Resonance Spectroscopy , Male , Middle Aged , Mitochondria, Muscle/metabolism , Muscle Weakness/etiology , Muscle Weakness/metabolism , Muscle, Skeletal/anatomy & histology , Muscle, Skeletal/drug effects , Renal Dialysis , Spectroscopy, Near-Infrared
2.
J Biol Chem ; 276(47): 44323-30, 2001 Nov 23.
Article in English | MEDLINE | ID: mdl-11555645

ABSTRACT

Hypoxia-inducible factor (HIF) mediates a widespread transcriptional response to hypoxia through binding to cis-acting DNA sequences termed hypoxia response elements (HREs). Activity of the transcriptional complex is suppressed in the presence of oxygen by processes that include the targeting of HIF-alpha subunits for ubiquitin-mediated proteolysis. To provide further insights into these processes we constructed Chinese hamster ovary (CHO) cells bearing stably integrated plasmids that expressed HRE-linked surface antigens and used these cells in genetic screens for mutants that demonstrated constitutive up-regulation of HRE activity. From mutagenized cultures, clones were isolated that demonstrated up-regulation of HRE activity and increased HIF-1alpha protein levels in normoxic culture. Transfection and cell fusion studies suggested that these cells possess recessive defects that affect one or more pathways involved in HIF-alpha proteolysis. Two lines were demonstrated to harbor truncating mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. In these cells, defects in ubiquitylation of exogenous human HIF-1alpha in vitro could be complemented by wild type pVHL, and re-expression of a wild type VHL gene restored a normal pattern of HIF/HRE activity, demonstrating the critical dependence of HIF regulation on pVHL in CHO cells. In contrast, other mutant cells had no demonstrable mutation in the VHL gene, and ubiquitylated exogenous HIF-1alpha normally, suggesting that they contain defects at other points in the oxygen-regulated processing of HIF-alpha subunits.


Subject(s)
DNA-Binding Proteins/physiology , Gene Expression Regulation/physiology , Genes, Tumor Suppressor , Ligases/genetics , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , von Hippel-Lindau Disease/genetics , Animals , Base Sequence , CHO Cells , Cell Fusion , Clone Cells , Cricetinae , DNA , Flow Cytometry , Genetic Complementation Test , Hydrolysis , Mice , Molecular Sequence Data , Mutation , Von Hippel-Lindau Tumor Suppressor Protein
3.
Blood ; 98(2): 296-302, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11435296

ABSTRACT

Hypoxia-inducible factor (HIF) mediates a large number of transcriptional responses to hypoxia and has an important role in processes that include angiogenesis and erythropoiesis. The HIF DNA binding complex consists of 2 basic-helix-loop-helix PAS proteins designated alpha and beta subunits. Regulation occurs principally through the alpha subunits, which are stabilized and activated in hypoxia. Although substantial evidence implicates reactive oxygen species (ROS) in the regulatory process, the precise mechanisms remain unclear. Mitochondria are an important source of ROS, and in one model it has been proposed that hypoxia increases the generation of ROS at complex III in the mitochondrion and that this signal acts through a transduction pathway to stabilize HIF-1alpha and to activate HIF. To test this model the induction of the HIF-1alpha subunit and the HIF target gene, glucose-transporter-1, was examined in a variety of mutant cells that lacked mitochondrial DNA (rho0) or had other genetic defects in mitochondrial respiration. HIF induction by hypoxia was essentially normal in all cells tested. Hydrogen peroxide production was measured by the luminol/peroxidase method and found to be reduced in rho0 versus wild-type cells and reduced by hypoxia in both rho0 and wild-type cells. Furthermore, concentrations of rotenone that maximally inhibited respiration did not affect HIF activation by hypoxia. These data do not support the model outlined above and indicate that a functional respiratory chain is not necessary for the regulation of HIF by oxygen.


Subject(s)
DNA, Mitochondrial/genetics , DNA-Binding Proteins/genetics , Electron Transport/genetics , Mitochondria/physiology , Nuclear Proteins/genetics , Transcription Factors , Animals , CHO Cells , Cell Hypoxia , Cell Line , Cricetinae , Cricetulus , DNA, Mitochondrial/analysis , DNA-Binding Proteins/analysis , Ethidium/pharmacology , Gene Expression Regulation/drug effects , Glucose Transporter Type 1 , Humans , Hydrogen Peroxide/analysis , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Lung Neoplasms , Mitochondria/drug effects , Monosaccharide Transport Proteins/genetics , Nuclear Proteins/analysis , Osteosarcoma , Oxygen Consumption , Polymerase Chain Reaction , Rotenone/pharmacology , Tumor Cells, Cultured
4.
Nature ; 399(6733): 271-5, 1999 May 20.
Article in English | MEDLINE | ID: mdl-10353251

ABSTRACT

Hypoxia-inducible factor-1 (HIF-1) has a key role in cellular responses to hypoxia, including the regulation of genes involved in energy metabolism, angiogenesis and apoptosis. The alpha subunits of HIF are rapidly degraded by the proteasome under normal conditions, but are stabilized by hypoxia. Cobaltous ions or iron chelators mimic hypoxia, indicating that the stimuli may interact through effects on a ferroprotein oxygen sensor. Here we demonstrate a critical role for the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL in HIF-1 regulation. In VHL-defective cells, HIF alpha-subunits are constitutively stabilized and HIF-1 is activated. Re-expression of pVHL restored oxygen-dependent instability. pVHL and HIF alpha-subunits co-immunoprecipitate, and pVHL is present in the hypoxic HIF-1 DNA-binding complex. In cells exposed to iron chelation or cobaltous ions, HIF-1 is dissociated from pVHL. These findings indicate that the interaction between HIF-1 and pVHL is iron dependent, and that it is necessary for the oxygen-dependent degradation of HIF alpha-subunits. Thus, constitutive HIF-1 activation may underlie the angiogenic phenotype of VHL-associated tumours. The pVHL/HIF-1 interaction provides a new focus for understanding cellular oxygen sensing.


Subject(s)
DNA-Binding Proteins/metabolism , Genes, Tumor Suppressor , Ligases , Nuclear Proteins/metabolism , Oxygen/metabolism , Proteins/metabolism , Transcription Factors , Tumor Suppressor Proteins , Ubiquitin-Protein Ligases , Cell Hypoxia , Cobalt/pharmacology , Cysteine Endopeptidases/metabolism , Gene Expression Regulation , HeLa Cells , Humans , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Iron Chelating Agents/pharmacology , Multienzyme Complexes/metabolism , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/metabolism , Proteasome Endopeptidase Complex , Protein Binding/drug effects , Response Elements , Transfection , Tumor Cells, Cultured , Von Hippel-Lindau Tumor Suppressor Protein , von Hippel-Lindau Disease/genetics , von Hippel-Lindau Disease/metabolism , von Hippel-Lindau Disease/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...